International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas

Masao Tanaka a  Suresh Chari b  Volkan Adsay c  Carlos Fernandez-del Castillo d  Massimo Falconi e  Michio Shimizu f  Koji Yamaguchi a  Kenji Yamao g  Seiki Matsuno h

aDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; bDepartment of Gastroenterology, Mayo Clinic, Rochester, Minn., USA; cDepartment of Pathology, Wayne State University and The Karmanos Cancer Center, Harper Hospital, Detroit, Mich., USA; dDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Mass., USA; eDepartment of Surgery, Verona University, Verona, Italy; fDepartment of Pathology, Saitama Medical School, Saitama, Japan; gDepartment of Pathology, Aichi Cancer Center, Nagoya, Japan, and hDepartment of Gastroenterological Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan

there remain ambiguities between the two diseases. In view of the increasing frequency with which these neoplasms are being diagnosed worldwide, it would be helpful for physicians managing patients with cystic neoplasms of the pancreas to have guidelines for the diagnosis and treatment of IPMN and MCN. The proposed guidelines represent a consensus of the working group of the International Association of Pancreatologists.

Introduction

Non-inflammatory cystic lesions of the pancreas are more common than previously recognized. In an autopsy study [1], small cystic lesions were found in nearly half of the 300 patients studied, the prevalence increasing with age. While most cysts were non-neoplastic, 3.4% of the patients had cysts that showed epithelial atypia [1]. It is therefore not surprising that with the increasing use of high-resolution abdominal imaging techniques, cystic
neoplasms of the pancreas are being increasingly identified, often as incidental findings [2].

In 1996, the World Health Organization (WHO) classified cystic mucin-producing pancreatic neoplasms into two distinct entities [3], i.e., intraductal papillary mucinous tumor and mucinous cystic tumor. In the revised WHO classification in 2000 [4], the two neoplasms were renamed as intraductal papillary mucinous neoplasm (IPMN) (fig. 1) and mucinous cystic neoplasm (MCN) (fig. 2), respectively. Since then much has been learnt about the clinical, radiographic, and histological characteristics of these neoplasms. For example, the presence of ovarian-type stroma has been proposed as a characteristic feature of MCN that distinguishes it from IPMN. While there have been rapid advances in our understanding of the prevalence of cancer at diagnosis and the risk of recurrence following resection, there are still considerable gaps in our knowledge of the natural history of these neo-
1. Definition and Classification

1a. It has been suggested that IPMNs arising in the branch ducts are less aggressive than those arising in the main duct. Can we preoperatively distinguish main duct IPMN from branch duct IPMN?

1b. In most IPMNs there are papillary growths in both the main duct and branch duct by histology. Do we still need the mixed category or should the mixed type IPMNs be considered as advanced branch duct IPMNs?

1c. Should ovarian-type stroma be a histological requirement for diagnosing MCN?

1d. If all mucinous neoplasms need resection, is distinction between MCN and IPMN merely an academic exercise?

2. Preoperative evaluation

2a. Can we reliably distinguish branch duct IPMN from MCN preoperatively? If so, which imaging modality is best to distinguish between branch duct IPMN and MCN? Is there a preferred order to the tests that should be performed?

2b. Is it possible to diagnose minimally invasive carcinoma derived from IPMN and MCN preoperatively?

3. Indication for resection

3a. Should all main duct IPMNs be resected? If not, what criteria should be employed to separate those that should be resected from those that can be watched (size, mural nodules, etc.)?

3b. Should all branch duct IPMNs be resected? If not, what criteria should be employed to separate those that should be resected from those that can be watched (size, mural nodules, etc.)?

3c. Should all MCNs be resected? If not, what criteria should be employed to separate those that should be resected from those that can be watched (size, mural nodules, etc.)?

4. Method of resection

4a. Pancreatectomy with lymph node dissection is necessary when an invasive carcinoma is suspected. What is an appropriate surgical procedure for non-invasive MCNs and IPMNs? Is pancreatectomy limited to some extent without lymph node dissection appropriate?

4b. Does limited resection (e.g., middle segmental pancreatectomy) have a role in surgical management of MCNs or IPMNs?

4c. What should be the approach to multifocal branch duct IPMNs? In an older patient, is it reasonable to resect the portion of the gland with the largest cyst(s) alone and follow clinically to avoid total pancreatectomy?

5. Histological questions

5a. What is the role of intraoperative frozen section consultation in the surgical management of patients with IPMNs and MCNs? In particular, should pancreatic parenchymal margins be frozen and what should be done if mucinous epithelium is identified in the larger or in the smaller pancreatic ducts?

5b. Are there special instructions for specimen processing in MCNs and IPMNs?

5c. Are there special instructions for specimen processing to differentiate branch duct IPMNs from main duct IPMNs?

6. Method of follow-up

6a. How should patients with non-resected IPMNs and MCNs be followed? How often should they be followed and which techniques should be employed as baseline investigations?

6b. How should patients with surgically resected IPMNs and MCNs be followed? How often should they be followed and which techniques should be employed as baseline investigations?

6c. Should care be taken to the possible occurrence of other malignant neoplasms in patients with IPMNs on follow-up?

1. It has been suggested that IPMN arising in the branch ducts are less aggressive than those arising in the main duct. Can we preoperatively distinguish main duct IPMN from branch duct IPMN?

IPMN can be classified as main duct IPMN or branch duct IPMN based on imaging studies or by histology [5]. On conventional imaging (i.e., computed tomography (CT) or magnetic resonance cholangiopancreatography (MRCP)), dilation of the main duct ≥ 1 cm strongly suggests main duct IPMN (fig. 3), whereas a presence of a pancreatic mucinous cyst communicating with the pancreatic duct without main duct dilation suggests branch neoplasms. However, in view of the increasing frequency with which these neoplasms are being diagnosed worldwide, it would be helpful for physicians managing patients with cystic neoplasms of the pancreas to have guidelines for the diagnosis and treatment of IPMN and MCN. No doubt, as our understanding grows, these guidelines will need revision.

During the Eleventh Congress of the International Association of Pancreatology held in Sendai, Japan, from July 11 through 14, 2004, we had a consensus meeting on this topic. The working group set up 6 clinical questions with 18 subdivisions (table 1), and continued to work on the answers. The proposed guidelines represent a consensus of the working group of the International Association of Pancreatology at this moment.
duct IPMN (fig. 4) [6–8]. The presence of the papillary growth in branch or main ducts can be ascertained with greater degree of certainty using more sophisticated and invasive imaging studies, such as endoscopic ultrasonography (EUS) (fig. 5) [9, 10], endoscopic retrograde cholangiopancreatography (ERCP) with or without the use of a balloon catheter (fig. 1a, b), intraductal ultrasonography (fig. 6) [11, 12] and peroral pancreatoscopy (fig. 7) [13, 14], or by a combination of intraductal ultrasonography and peroral pancreatoscopy [15]. However, these techniques are not widely available. The most definitive classification of IPMN into main or branch duct type is made by histology, provided the resected specimen is properly sectioned.
Main duct IPMN and branch duct IPMN have significant differences in prevalence of cancer ranging from 57 to 92% [16–24] and 6 to 46% [16–23], respectively (tables 2, 3) and therefore the classification has prognostic implications. In practice, patients classified as branch duct IPMN based on preoperative imaging studies sometimes show microscopic involvement of the main duct not detectable preoperatively. It is unclear if such subjects with ‘predominantly’ branch duct IPMN with microscopic main duct involvement have a higher prevalence of malignancy compared to those with dysplasia confined solely to the branch duct.

1b. In most IPMNs there are papillary growths in both the main duct and branch duct by histology. Do we still need the mixed category or should the mixed type IPMNs be considered as advanced branch duct IPMNs?

The categorization of IPMN according to the differential involvement of the branch vs. main duct is mostly based on imaging findings, and as such this classification scheme appears to have substantial value in preoperative management algorithms for IPMN. The role of this classification, however, may be overridden once the neoplasm is resected, re-evaluated pathologically, and graded as adenoma, borderline, CIS or invasive. On the other hand, there are significant pathologic correlates of this classification: IPMNs categorized as ‘branch type’ by radiographic methods are typically found to be smaller, less complex (less papillary), and non-malignant (more commonly adenomas with gastric/foveolar type epithelium), which explains why many branch duct IPMNs have been successfully managed by conservative therapy, even ‘wait and watch’.

One pitfall in this classification scheme, however, is that many of the branch duct IPMNs prove, by microscopic examinations, to have some degree of involvement in the main duct as well. Therefore, predominantly main duct type and predominantly branch duct type may be a more accurate conceptualization of these categories, al-

<table>
<thead>
<tr>
<th>Reference (first author)</th>
<th>Year published</th>
<th>Patients</th>
<th>Malignant including CIS, %</th>
<th>Invasive malignancy, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kobari [16]</td>
<td>1999</td>
<td>13</td>
<td>92</td>
<td>23</td>
</tr>
<tr>
<td>Terris [17]</td>
<td>2000</td>
<td>30</td>
<td>57</td>
<td>37</td>
</tr>
<tr>
<td>Doi [18]</td>
<td>2002</td>
<td>12</td>
<td>83</td>
<td>Not stated</td>
</tr>
<tr>
<td>Matsumoto [19]</td>
<td>2003</td>
<td>27</td>
<td>63</td>
<td>Not stated</td>
</tr>
<tr>
<td>Choi [20]</td>
<td>2003</td>
<td>34</td>
<td>85</td>
<td>Not stated</td>
</tr>
<tr>
<td>Kitagawa [21]</td>
<td>2003</td>
<td>37</td>
<td>65</td>
<td>54</td>
</tr>
<tr>
<td>Sugiyama [22]</td>
<td>2003</td>
<td>30</td>
<td>70</td>
<td>57</td>
</tr>
<tr>
<td>Sohn [23]</td>
<td>2004</td>
<td>69</td>
<td>Not stated</td>
<td>45</td>
</tr>
<tr>
<td>Salvia [24]</td>
<td>2004</td>
<td>140</td>
<td>60</td>
<td>42</td>
</tr>
<tr>
<td>Mean of all series</td>
<td></td>
<td>70</td>
<td>43</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reference (first author)</th>
<th>Year published</th>
<th>Patients</th>
<th>Malignant including CIS, %</th>
<th>Invasive malignancy, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kobari [16]</td>
<td>1999</td>
<td>17</td>
<td>31</td>
<td>6</td>
</tr>
<tr>
<td>Terris [17]</td>
<td>2000</td>
<td>13</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Doi [18]</td>
<td>2002</td>
<td>26</td>
<td>46</td>
<td>Not stated</td>
</tr>
<tr>
<td>Matsumoto [19]</td>
<td>2003</td>
<td>16</td>
<td>6</td>
<td>Not stated</td>
</tr>
<tr>
<td>Kitagawa [21]</td>
<td>2003</td>
<td>26</td>
<td>35</td>
<td>31</td>
</tr>
<tr>
<td>Sugiyama [22]</td>
<td>2003</td>
<td>32</td>
<td>40</td>
<td>9</td>
</tr>
<tr>
<td>Sohn [23]</td>
<td>2004</td>
<td>60</td>
<td>Not stated</td>
<td>30</td>
</tr>
<tr>
<td>Mean of all series</td>
<td></td>
<td>25</td>
<td>15</td>
<td></td>
</tr>
</tbody>
</table>
though the word predominantly is omitted for practical purposes. In fact, ‘branch limited’ vs. ‘beyond the branch’ may be even more accurate. On the other hand, there are more important and practical implications of this conceptual issue. First, it is difficult to determine how much of the main duct involvement is necessary to qualify the lesion as ‘main duct IPMN’. In this regard, more clinical follow-up data need to accumulate before the criteria for this distinction can be established. In the meantime, however, the criteria advocated for the definition of IPMN in the recent international consensus manuscript [25] may be applicable for practical purposes. Even when these criteria are applied, however, many IPMNs would still fall into a mixed category. Therefore, it is necessary to retain this mixed category until future studies further clarify the criteria to distinguish these two groups.

Since clinicopathologic correlation is imperative in the management of IPMNs as well as in understanding the biologic behavior of the subsets of this type of neoplasm, it is recommended that surgical pathologists make every attempt to determine branch vs. main duct type, if nothing else, in order to provide verification to this clinical classification. For this purpose, the findings regarding the distribution of ductal involvement may be communicated in a note or comment following the main diagnosis in the surgical pathology report.

1c. Should ovarian-type stroma be a histological requirement for diagnosing MCN?

The most characteristic histological finding in MCN is the presence of a unique ovarian-type stroma (fig. 8) [26] not found in other pancreatic neoplasms. This ovarian-type stroma forms a layer of variable thickness beneath the epithelial lining. The stromal cells have oval nuclei and spindled cytoplasm, and are arranged in long fascicles. The resemblance to ovarian stroma is further...
strengthened by the presence of occasional ‘lutenized’ cells – epithelioid cells with abundant clear cytoplasm. A study of 34 pancreatic MCN and 10 ovarian MCN showed that the ovarian stroma of MCN from the two organs shared the same immunohistochemical and histological characteristics [27].

Like its ovarian counterpart, the stroma of pancreatic MCN variably stains for estrogen and progesterone receptors (fig. 8b,c), with 61.8% of pancreatic MCN staining for human chorionic gonadotropin [27].

The most important question with regard to the accurate classification of MCN and its differentiation from branch duct form of IPMN is whether the presence of ovarian-type stroma is required to diagnose MCN. Three studies on MCN have used ovarian-type stroma as a requisite criterion for diagnosis of MCN [28–30]. When defined by the presence of ovarian-type stroma, MCN has a distinct demographic profile; it occurs almost exclusively in women and is almost always found in the pancreatic body/tail region [28, 29]. It has been argued that theoretically it may be possible that postmenopausal women and men with MCN may fail to demonstrate ovarian-type stroma. In a study of 56 MCN defined strictly by presence of ovarian stroma, 9 patients (16%) were >60 years of age [28]. Also, there are male patients with mucinous cystadenoma with ovarian-type stroma [28, 31].

In the absence of a definitive marker, other than ovarian-type stroma, to distinguish MCN from IPMN, it is currently impossible to say if neoplasms classified on the basis of any criterion other than presence of ovarian-type stroma (for example, non-communication with the duct) are indeed MCN. It has become clear over the past few years that making exceptions to the ovarian-type stroma rule frequently leads to misclassification of IPMN as MCN [28]. Therefore the term MCN should be restricted to neoplasms exhibiting ovarian-type stroma.

Clearly, typical MCN with ovarian-type stroma is rare in males and it is less common in postmenopausal women than in women of childbearing age. Occasionally, mucin-producing pancreatic cystic lesions are seen in men or postmenopausal women that neither have ovarian-type stroma nor have typical histological features seen in branch duct IPMNs such as a thin wall, grape-like appearance and a communication with the pancreatic duct. Rather than classify such lesions as MCNs, we propose the use of the term ‘indeterminate mucin-producing cystic neoplasm of the pancreas’. In future, when specific markers of IPMN and MCN become available, these lesions may be more definitively classified.

Id. If all mucinous neoplasms need resection, is distinction between MCN and IPMN merely an academic exercise?

The general recommendation has been that all mucin-producing neoplasms undergo resection in view of their malignant potential, which questions the clinical utility of careful differentiation of MCN from IPMN [30, 32–34]. However, there are crucial differences between MCN and IPMN with regard to pathogenesis, multifocality, need for follow-up and prevalence of cancer that impact clinical management.

Due to its close histological and immunohistochemical resemblance to ovarian mucinous cystadenomas, MCN has been postulated to arise from ovarian rests in the pancreas [29]. IPMN appears to arise from the pancreatic duct.

MCN and IPMN also have important clinical differences. MCNs are generally solitary and do not recur after complete resection [35, 36]. On the other hand, branch duct IPMNs have been reported to be multifocal in distant regions of the pancreas in up to 30% of patients [37–39], and there is at least a 10% recurrent rate in those patients with non-invasive IPMN who undergo partial pancreatic resection with negative margins [40]. Thus, while no follow-up is needed after resection of non-invasive MCN, young patients with IPMN need follow-up, especially if they have unresected synchronous lesions.

The prevalence of invasive carcinoma reported in MCN has varied widely from 6 to 36% [28–30]. However, data on prevalence of invasive carcinoma in MCN are hard to interpret as few studies have used ovarian-type stroma as a necessary criterion for diagnosis of MCN. Even in studies restricted to neoplasms with ovarian-type stroma the prevalence of cancer has varied from 6 to 27% [28, 29]. In IPMN, prevalence of invasive carcinoma at diagnosis has been reported to be high in main duct IPMN (23–57%, table 2) and lower in branch duct IPMN (0–31%, table 3).

2. Preoperative Evaluation

2a. Can we reliably distinguish branch duct IPMN from MCN preoperatively? If so, which imaging modality is best to distinguish between branch duct IPMN and MCN? Is there a preferred order to the tests that should be performed?

There are some obvious differences in clinicopathological features between IPMN and MCN with ovarian-type stroma (table 4) [28–30, 41–47]. Understanding of...
these distinctive features and characteristics of each imaging modality lead to differentiation of the two diseases in most patients. Cystic lesions in males and those in the head of the pancreas are unlikely to be MCN. Magnetic resonance imaging (MRI) with MRCP is the best to outline the gross appearance. Communication with the pancreatic duct demonstrated on imaging studies such as ERCP (most reliable), MRCP (helpful), and EUS (of some help) strongly suggests branch duct IPMN. However, even ERCP in branch duct IPMN may fail to fill the cystic side branch due to mucus plugging the communication. On the other hand, there has been a report of a histologically proven MCN showing communication with pancreatic ducts [47]. In some patients it may therefore be impossible to distinguish between the two entities with certainty preoperatively.

2b. Is it possible to diagnose minimally invasive carcinoma derived from IPMN and MCN preoperatively?

The Japan Pancreas Society (JPS) defined a non-invasive type of intraductal papillary mucinous carcinoma as limited to the pancreatic duct and a minimally invasive type as having invaded slightly beyond the ductal wall [48]. However, this definition is not so clear. If the minimally invasive intraductal papillary mucinous carcinoma is defined as microscopic cancer invasion to the pancreatic parenchyma, it is impossible to diagnose the minimal invasion preoperatively [49] at present as is the case in minimally invasive MCN.

3. Indication for Resection

3a. Should all main duct IPMNs be resected? If not, what criteria should be employed to separate those that should be resected from those that can be watched (size, mural nodules, etc.)?

The frequency of malignancy (in situ and invasive) in main duct IPMNs in 8 recent series from Japan, Europe, and the USA has ranged between 60 and 92%, with a mean of 70% [16–24], and approximately two-thirds of these malignant neoplasms have been invasive (table 2). In many studies there has been an attempt to identify radiologic or clinical characteristics that predict malignancy, although unfortunately many of these analyses have been made without separating main duct from branch duct variants. In a series reported by Sugiyama et al. [22], univariate analysis showed that presence of symptoms, a main pancreatic duct diameter >15 mm, and mural nodules were all significant predictors of malignancy in main duct or mixed type IPMNs, although there were patients without nodules or such marked pancreatic duct dilation that had in-situ or invasive carcinoma. The largest published series on main duct IPMNs combines the experiences of the Massachusetts General Hospital and the University of Verona [24]. This study comprised 140 patients, and found that patients with malignant neoplasms were significantly older (by 6.4 years), and had a higher likelihood of presenting with jaundice and/or worsening of diabetes; however, the study also showed that 29% of patients with malignant IPMNs involving the main duct were asymptomatic, and therefore reliance on symptoms could not exclude malignancy. Given the high prevalence of cancer and the data from the reviewed studies it is unlikely that any combination of clinical and radiological

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>MCN</th>
<th>Branch duct IPMN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (% female)</td>
<td>&gt;95%</td>
<td>~ 30%</td>
</tr>
<tr>
<td>Age (decade)</td>
<td>4th and 5th</td>
<td>6th and 7th</td>
</tr>
<tr>
<td>Location (% body/tail)</td>
<td>95%</td>
<td>~ 30%</td>
</tr>
<tr>
<td>Common capsule</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Calcification</td>
<td>Rare, curvilinear, in the wall of cyst</td>
<td>No</td>
</tr>
<tr>
<td>Gross appearance</td>
<td>Orange-like</td>
<td>Grape-like</td>
</tr>
<tr>
<td>Internal structure</td>
<td>Cysts in cyst</td>
<td>Cyst by cyst</td>
</tr>
<tr>
<td>Pancreatic duct communication</td>
<td>Infrequent</td>
<td>Yes (though not always demonstrable)</td>
</tr>
<tr>
<td>Main pancreatic duct</td>
<td>Normal or deviated</td>
<td>Normal, or if dilated, suggests combined type</td>
</tr>
</tbody>
</table>
parameters will accurately discriminate between malignant and non-malignant main duct IPMNs. Furthermore, evidence of ‘clonal progression’ in these neoplasms [50] and the age difference between patients with malignant and benign lesions (which was also shown in another large study) [30] are indicative that most if not all benign main duct IPMNs may progress into invasive cancer, and the long-term follow-up of resected patients shows excellent survival for benign and non-invasive neoplasms and 5-year survival between 36 and 60% for invasive carcinomas [21, 23, 24, 40]. Based on this, our current recommendation is to resect all main duct and mixed variant IPMNs as long as the patient is a good surgical candidate with a reasonable life expectancy. It is important that resections for IPMNs be carried out by surgeons familiar with this diagnosis and in centers where pancreatic surgery can be done safely.

3b. Should all branch duct IPMNs be resected?

Review of 7 recent series describing branch duct IPMNs shows a frequency of malignancy between 6 and 46%, with a mean of 25%, and a frequency of invasive cancer ranging between 0 and 31%, with a mean of 15% (table 3) [16–23]. It is of note that the two studies with the highest frequency of invasive cancer (30 and 31%, respectively) do not describe asymptomatic patients within their series [21, 23], whereas other series with low prevalence of invasive cancer show a significant proportion of incidentally discovered IPMNs [17, 19, 22]. In the series of Sugiyama et al. [22], 53% of branch duct IPMNs were asymptomatic, and none of those patients had invasive cancer. Two studies from Japan have looked at morphologic features of branch duct IPMNs and risk of malignancy. Matsumoto et al. [19] found no malignancy (in situ or invasive) in neoplasms measuring <30 mm and without mural nodules, and described non-operative management in 12 patients with branch duct IPMNs who either refused operation or were at high surgical risk. The majority of these patients were asymptomatic, and had no radiologic progression of their neoplasms during an average follow-up of 33 months. In the second study, Sugiyama et al. [22] found with multivariate analysis that the size >30 mm and presence of mural nodules were the strongest predictors of malignancy in branch duct IPMNs. Only 1/15 patients with a neoplasm <30 mm had in-situ carcinoma (none had invasive cancer), and only 5/22 patients without mural nodules had malignancy. Thus, the overall lower prevalence of malignancy in branch duct IPMNs and the reassurance from the above studies that the likelihood of invasive cancer is very low in small cysts raise the possibility of management with careful observation in asymptomatic patients. Patients with branch duct IPMNs who are symptomatic should be treated with resection not only to alleviate the symptoms, but also because of a higher likelihood of malignancy. It is important to emphasize that the decision to treat should be individualized and based on patient preferences and willingness or unwillingness to undergo follow-up studies, as well as on the availability of safe pancreatic resection. Moreover, more data based on pathological studies of branch duct IPMNs >30 mm and without main duct dilation or mural nodules are needed to determine if all branch duct IPMNs >30 mm in size should be resected immediately.

3c. Should all MCNs be resected? If not, what criteria should be employed to separate those that should be resected from those that can be watched (size, mural nodules, etc.)?

Unless there are contraindications for operation, all MCNs should be resected. Usually these neoplasms are localized in the body-tail of the gland and affect middled-aged women [29, 35, 36]. Current thinking is that all MCNs may progress to malignancy, and the life expectancy of most of these patients will allow development of mucinous cystadenocarcinoma, which has a very low resectability and a very poor prognosis [35, 36]. Furthermore, the operation, usually a left pancreatectomy, has a low morbidity and practically no mortality [51]. Predictors of malignancy such as large size, mural nodules, and eggshell calcification [32] mean only that spleen preserving techniques, either laparoscopically or open, must be avoided in order to obtain a correct oncological lymph node dissection [52–55].

4. Method of Resection

4a. Pancreatectomy with lymph node dissection is necessary when an invasive carcinoma is suspected. What is an appropriate surgical procedure for non-invasive MCNs and IPMNs? Is pancreatectomy limited to some extent without lymph node dissection appropriate?

It is not always easy to assess pre- and intraoperatively the grade of invasiveness [56]. Whenever any doubt exists, a typical resection (pancreatoduodenectomy, left pancreatectomy, total pancreatectomy according to the site and the extension of the disease) with lymph node dissection must be pursued [34, 57]. In very limited size lesions, without any laboratory, clinical or radiological
suspicion of malignancy, limited resections can be planned, but should always be contingent on a careful intraoperative final assessment.

4b. Does limited resection (e.g., middle segmental pancreatectomy) have a role in surgical management of MCNs or IPMNs?

The aim of limited pancreatic resection is to preserve exocrine and endocrine pancreatic functions. Newer understanding of surgical anatomy of the pancreas has led to the proposal of various types of limited pancreatectomy [58, 59]. However, limited pancreatectomy has its problems, including technical difficulty (mostly related to a complicated surgical anatomy), a higher incidence of postoperative complications including pancreatic fistulae, and the risk of recurrence from potentially residual neoplasm. For pancreatic head lesions, duodenum-preserving pancreas head resection [60–62], pancreatic head resection with second portion duodenectomy [63], ventral pancreatectomy [64], resection of uncinate process [65], and ductal branch-oriented minimal pancreatectomy [66] have been proposed, for pancreatic body diseases, a dorsal pancreatectomy [67] and middle segmentectomy [68, 69], and for pancreatic tail neoplasms, spleen-preserving distal pancreatectomy [52–54]. Branch duct IPMNs with possible in-situ carcinoma and MCNs can be candidates for limited pancreatectomy as far as negative ductal margins can be obtained and safe pancreatectomy can be performed but no good follow-up data on recurrence are available.

4c. What should be the approach to multifocal branch duct IPMNs? In an older patient, is it reasonable to resect the portion of the gland with the largest cyst(s) alone and follow clinically to avoid total pancreatectomy?

Branch duct IPMNs can often be multifocal and located in distant segments of the pancreas (fig. 9). This is especially evident when EUS or MRCP is performed. It is unclear if multifocality confers a higher risk of invasive cancer than that predicted by the cyst size alone. If there is an indication for surgical resection (i.e., the patient is symptomatic, or the lesions are >3 cm and/or have mural nodules), a decision to proceed with a total pancreatectomy in order to remove all the lesions must be weighed carefully against the ability of the patient to manage the metabolic consequences of an apancreatic state. The age of the patient plays an important role in this decision, since the longer the life expectancy, the greater the risk of development of invasive cancer. While some studies have suggested a time lag of 5–7 years between adenomas and carcinomas (based on age differences of resected patients with benign and malignant IPMNs) [23, 24], in reality there is practically no information on the natural history of branch duct IPMNs, and it may be equally reasonable to resect the dominant lesion and observe the remainder until they become symptomatic or growth is documented.

5. Histological Questions

5a. What is the role of intraoperative frozen section consultation in the surgical management of patients with IPMNs and MCNs? In particular, should pancreatic parenchymal margins be frozen and what should be done if mucinous epithelium is identified in the larger or in the smaller pancreatic ducts?

The role of frozen section for MCNs is somewhat different from that for IPMNs:

Frozen Section for IPMNs

Frozen section of the surgical margins has an important role in the intraoperative management of IPMNs. Microscopic extension of the neoplastic cells beyond the grossly (radiologically and macroscopically) visible boundaries of the main lesion is a common occurrence in IPMNs, and this often needs to be investigated by performing a frozen section.

Caution should be exercised in interpreting the frozen section result, keeping in mind the following concerns:
(1) It should be remembered that even a negative margin does not assure the absence of neoplastic cells in the remaining pancreas. It has been well documented that IPMNs can be multifocal, and that there are sometimes ‘skip’ lesions in IPMNs, with non-neoplastic tissue intervening neoplastic foci. Along similar lines, there is also evidence that IPMNs may, in some instances, be a marker of invasive carcinoma [70]. This is exemplified by the cases that have an IPMN in the pancreatic head and a seemingly independent invasive ductal carcinoma in the tail of the organ. In other words, in some patients, IPMN may be a marker of a field defect and propensity for cancer formation in the pancreas, in some cases, away from the IPMN itself. Therefore, every effort should be made, preoperatively and intraoperatively, to rule out the presence of the neoplasm in the remaining pancreas. Furthermore, it has been well documented that a third of the IPMN patients have a separate malignancy in other organs [71, 72].

(2) It should also be remembered that grading of IPMNs can be subjective, and frozen tissue exhibit artifacts that accentuate the difficulty in interpretation of the histomorphologic findings. The decision to resect additional pancreatic parenchyma should be individualized and based on careful discussion between the surgeon and pathologist. A problem commonly encountered is denuded epithelium, where evaluation of the margin becomes impossible. To avoid this, gentle handling of the tissue (both in the operating room and the laboratory) is necessary. Stepwise sections of the tissue in the laboratory or even re-melting and re-embedding the reverse side of the tissue (i.e., if the fragment has not been oriented) may be considered.

Management of Positive Margins in IPMNs
The relative risk and biologic significance of various grades and subsets of IPMNs have not yet been fully established. However, the following assumptions can be made based on the current data in the literature:

IPMN Adenoma. It is generally believed that IPM adenomas do not warrant further resection. This impression mostly stems from the fact that most branch duct IPMNs have been successfully followed up for decades, and only rarely developed invasive cancer. These branch duct IPMNs are typically adenomas (with no cytoarchitectural atypia) and have gastric/foveolar type epithelium, the type that used to be classified as ‘IPMT (intraductal papillary-mucinous tumor) hyperplasia’ in the JPS classification system [48, 73]. Whether these represent hyperplasia or adenoma is a discussion beyond the scope of this article. Regardless of the term, it is generally believed that such lesions bear only minimal risk of progression to cancer, which warrants close follow-up of the patient but does not justify (further) operation. Along the same lines, if a coincidental low-grade PanIN (1 and 2) is encountered in a resection margin, it is believed that no further resection is necessary. This impression is based on the fact that PanIN-1 and -2 are common incidental findings in the general population [40, 74].

IPMN with Borderline Atypia. This category is difficult to characterize and hence its management decision is also difficult. Not surprisingly, some of these borderline lesions are closer to adenomas and hence assumed to be less clinically significant and may not require further resection. On the other hand, those that have florid papillary formation (with villous-intestinal or pancreatobiliary patterns) may warrant further attention [75]. Typically, if there are florid papillary nodules at the margin, there are a lot more papillary nodules in the remaining pancreas, some of which prove to have higher-grade dysplasia in further examination. Therefore, such lesions may require further resection, if clinically indicated.

IPMN with CIS or Invasive Carcinoma. The relative risk of ‘progression’ and fatal outcome in IPMNs is difficult to calculate. Even patients with tubular type invasive carcinoma arising in IPMNs sometimes experience a more protracted clinical course than those with conventional ductal adenocarcinoma of this organ. Nevertheless, there is general consensus that IPMNs with CIS or invasive carcinoma are potentially fatal diseases if left untreated, and ought to be completely resected whenever feasible. To a lesser degree, the same may also apply to PanIN-3, which may be coincidentally encountered in patients with IPMN [76]. It should be noted that in some patients with IPMNs, it is difficult to determine whether some of the neoplastic changes within the small ducts represent PanINs or IPMNs [40, 77, 78]. At this point, this question is more an academic exercise than a practical issue, because, if such a lesion is encountered at the margin, the management should be based on the degree of cytologic atypia, and if frank CIS is noted, further resection may be attempted, if clinically indicated.

Frozen Section for MCNs
For MCNs, the role of frozen section appears to be more limited. Typically, MCNs have thick-walled cysts and their boundaries are easily discernible. The vast majority forms a localized mass in the tail or body, and unlike in IPMNs, microscopic extension of the lesion into the seemingly uninvolved pancreas is very uncommon. However, frozen section is indicated to rule out invasive
carcinoma, in particular, if a dubious firmness is close to the resection margin. If invasive carcinoma is detected at the margin, it ought to be treated as any other invasive carcinoma of this organ. Rarely, an incidental PanIN may also be detected at the margin. As discussed previously, PanIN-1 and -2 are common incidental findings, including in pancreata with MCNs [74, 79]. These are generally regarded as clinically inconsequential. Coincidental PanIN-3, on the other hand, is exceedingly uncommon in the absence of ductal adenocarcinoma. If encountered at the margin, PanIN-3 may require further attention.

5b. Are there special instructions for specimen processing in MCNs and IPMNs?

In IPMNs and MCNs, in-situ and invasive carcinoma may be multifocal and macroscopically (grossly) invisible. Therefore, it is not possible to rule out the presence of carcinoma unless the neoplasm is examined thoroughly. This is probably the main reason for the discrepancy in the literature regarding the value of grade (classification as adenoma, borderline, CIS, etc.) in these neoplasms [26, 30, 36]. It appears that undergrading due to undersampling is possibly the main reason for the ‘unexpectedly’ aggressive clinical course of some lower-grade examples of IPMNs and MCNs. Accordingly, some authors advocate pathologic sampling of the entire neoplasm [36, 40].

5c. Are there special instructions for specimen processing to differentiate branch duct from main duct IPMNs?

Once the neoplasm is resected and examined pathologically, the significance of classifying an IPMN as branch duct vs. main duct type is largely overridden by the other pathologic parameters such as the presence, type and extent of invasive carcinoma or grading of the IPMN component. Nevertheless, there is some evidence that branch duct IPMN may be a distinct subset, and it is suggested that the pathologists make every attempt to classify the process as branch duct or main duct type by documenting the distribution of the lesion in the ductal system. There are no special instructions for specimen processing for this purpose. However, it should be kept in mind that there are no reliable histological features to distinguish main ducts from the branch ducts in the pancreas by microscopic examination alone, especially when the duct is dilated by IPMN. Therefore, careful dissection of the specimen and proper identification of the main duct in the sections guide (either in a text form or by a diagram) is imperative in documenting the findings in the main duct. There are different approaches to dissection of these specimens, and the Japanese approach is well described in the textbook [80]. Taking a photo and a photocopy of the gross cut sections makes it easy to compare the relationships between the lesion and the main and/or branch duct.

6. Method of Follow-Up

6a. How should patients with non-resected IPMN and MCN be followed? How often should they be followed and which techniques should be employed as baseline investigations?

The decision to follow rather than resect a pancreatic cystic lesion is a matter of clinical judgment based on the age of the patient, comorbidities, and estimation of the cancer risk in the lesion. It is clear that the risk of prevalent cancer is high in main duct IPMN (table 2). Although this has not been formally studied, a review of studies on branch duct IPMN suggests that the prevalence of invasive cancer may be high (up to 30%) in symptomatic branch duct IPMN and low (0–5%) in those with asymptomatic branch duct IPMN. There are few reports in the English literature on identifying predictors of malignancy in asymptomatic mucinous lesions [22]. There have been four reports in the English literature describing the natural history of pancreatic IPMN evaluated by ERCP, CT or MRCP [81–84].

Based on limited available data from these studies it appears that asymptomatic cystic lesions without main duct dilation (>6 mm), those without mural nodules, and those <30 mm in size have a low risk of prevalent cancer and a low risk of progressing to invasive cancer in near-term (12- to 36-month) follow-up.

Ideally the imaging modality at baseline and follow-up should provide adequate information regarding the size of the lesion, size of the main pancreatic duct, and presence of intramural nodules. At least the first two criteria can be assessed satisfactorily by using non-invasive imaging studies such as multidetector high-resolution CT or MRCP, or by more invasive tests such as EUS. Assessment for intramural nodules requires EUS. Transabdominal ultrasonography is useful for follow-up in thin patients with clearly visualized cysts.

The interval between follow-up examinations remains to be determined. However, until definitive studies are performed to answer this question, it would appear reasonable to do yearly follow-up if lesion is <10 mm in size, 6–12 monthly follow-up for lesions between 10 and 20 mm, and 3–6 monthly follow-up for lesions >20 mm.
On follow-up studies, appearance of symptoms attributable to the cyst (e.g., pancreatitis), presence of intramural nodules, cyst size >30 mm, dilation of the main pancreatic duct (>6 mm) would be indications for resection. The interval of follow-up can be lengthened after 2 years of no change.

**6b. How should patients with surgically resected IPMNs and MCNs be followed? How often should they be followed and which techniques should be employed as baseline investigations?**

Patients with resected benign MCNs do not need follow-up, since several studies have shown that the risk of recurrence following resection is nil [29, 35]. Patients with resected malignant MCNs do have a significant risk of recurrence, and should be followed up every 6 months regarding local recurrence and distant metastasis (mainly hematogenous) using either CT or MRI. Patients with resected benign IPMNs do have a risk of recurrence in the remaining pancreas, and if it occurs can benefit from further resection. The frequency of this event and its relationship to surgical margins (i.e., positive, negative or indeterminate) is not clear, since most series thus far have had relatively short median follow-up, but seems to be at least 7% in non-invasive IPMN [23, 24, 40]. There is no evidence in the literature to define the frequency and type of surveillance that is required to detect these recurrences. One study suggests only clinical follow-up, and imaging if symptoms appear [40], but it is not clear if imaging in absence of symptoms could be beneficial by detecting earlier lesions. It may be reasonable to get yearly follow-up with CT or MRI, and then space this interval if no changes have occurred over several years. Patients with invasive IPMNs do have a significant risk of recurrence, and probably should be evaluated every 6 months. Serum levels of CEA and CA19-9 have no proven value in the follow-up of these patients, and if obtained it should be done for the purposes of research.

**6c. Should care be taken to the possible occurrence of other malignant neoplasms in patients with IPMNs on follow-up?**

There have been several reports in the English literature describing the high prevalence of malignant neoplasms in patients with IPMNs but not in those with MCNs. Yamaguchi et al. [85] reported that 27% of 48 patients with IPMNs had synchronous or metachronous malignant neoplasms in the stomach, colon, rectum, lung, breast, liver, but only in 5% of 21 patients with MCNs. Sugiyama and Atomi [71] also documented that 32% of 42 patients with IPMNs developed extrapancreatic malignant neoplasms. Adsay et al. [72] found a history of another malignancy in 29% or 8 of 28 patients with IPMNs. Osanai et al. [86] gave a 24% prevalence of extrapancreatic malignancies in a large series of 148 patients with IPMNs. Furthermore, Yamaguchi et al. [70] reported synchronous or metachronous occurrence of pancreatic cancer of ordinary type in the pancreas harboring IPMNs. Although there is not yet definitive evidence, care should be taken to the possible occurrence of malignant neoplasms in the pancreas and other organs in patients with IPMNs on follow-up.

---

**Fig. 10.** Algorithm for the management of branch duct IPMN.

* The interval of follow-up can be lengthened after 2 years of no change.


Acknowledgements

The authors thank Dr. Michael G. Sarr, Department of Surgery, Mayo Clinic and Foundation, for his suggestion on the working group members, and Dr. Ralph Hruban, Department of Pathology, of Johns Hopkins University, for his critical comments on the manuscript. The contribution of the following members of the Japanese Group of Investigators of IPMN and MCN is also acknowledged: Makoto Sunamura (Tohoku University), Satoshi Kondo (Hokkaido University), Hiroyuki Maguchi (Teine Keijinkai Hospital), Satoshi Tanno (Asahikawa Medical College), Wataru Kimura (Yamagata University), Toru Furukawa (Tohoku University), Naotaka Fujita (Sendai City Medical Center), Takashi Hatori (Tokyo Women’s Medical University), Masanori Sugiyama (Kyorin University), Terumi Kamisawa (Tokyo Metropolitan Komagome Hospital), Takayuki Tohma (Chiba University), Kazuo Inui (Fujita Health University), Tsutomu Fujii (Nagoya University), Akio Yanagisawa (Kyoto Prefectural University), Ryouichiro Doi (Kyoto University), Akihiko Nakaizumi (Osaka Medical Center for Cancer and Cardiovascular Diseases), Yoshiaki Murakami (Hiroshima University), Tetsuhide Itoh (Kyushu University), Shinichiro Ryu (Fukuoka University).

References


26 Campagna J, Oertel JE: Mucinous cystic neo-
plasms of the pancreas with overt and latent
malignancy (cystadenocarcinoma and cystad-
enoma). A clinicopathologic study of 41 cases.

27 Izumo A, Yamaguchi K, Eguchi T, Nishiyama K, Yamamoto H, Yonemasa H, Yao T, Tana-
ka M, Tsurenushi M: Mucinous cystic tumor of the pancreas: immunohistochemical assess-

28 Reddy RP, Smyrk TC, Zapiach M, Levy MJ, Pear-
son RK, Clain JE, Farnell MB, Sarr MG, Charl ST: Pancreatic mucinous cystic neo-
plasm defined by ovarian stroma: demographic,
1031.

29 Zamboni G, Scarpa A, Bogina G, Iacono C,
Bashi C, Talamini G, Sessa F, Capella, C., Sol-
cia E, Rickaert F, Mariuzzi GM, Kloeppel G:
Mucinous cystic tumors of the pancreas: clinico-
pathological features, prognosis, and relation-
ship to other mucinous cystic tumors. Am J

30 Thompson LD, Becker RC, Przygodzki RM, Adair CF, Heffess CS: Mucinous cystic neo-
plasm (mucinous cystadenocarcinoma of low-
grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am J

pancreatic mucinous cystadenoma in a man with mesenchymal stroma, expressing oestro-

32 Warshaw AL, Compton CC, Lewandrowski K, Cardenosa G, Mueller PR: Cystic tumors of the pancreas. New clinical, radiologic, and patho-

33 Nakagohri T, Nakao A, Inoue S, Sugimoto H,
Hatsuno T, Ito A, Hirooka Y, Nagasaki T, Na-
kashima N: Intraoperative ultrasonography by
high-resolution annular array transducer for
intraductal papillary mucinous tumors of the

34 Kaneko T, Nakao A, Nomoto S, Furukawa T,
Hirooka Y, Nakashima N, Nagasaka T: Intra-
operative pancreatoscopy with the ultrathin
pancreatoscope for mucin-producing tumors of
the pancreas. Arch Surg 1998;133:263–
267.

35 Fuji T, Obara T, Maguchi H, Tanno S, Ura H,
Kohgo Y: Clinicopathological study of mucin-
producing tumors of the pancreas: multicen-
tric development of carcinoma through atypi-
ical hyperplasia (in Japanese with English
11:344–352.

36 Charis, Yadav, Smyrk TC, DiMagno EP, Mi-
ller LJ, Massimo M, Norton IA, Farnell MB, Szarr MG: Study of recurrence af-

ers after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.
Gastroenterology 2002;123:1500–1507.

37 Biasiutti C, Fornasa F, Venturini S, Pagnotta
N, Schel, G, Procacci C: Mucinous cystic tu-

mors in Procacci C, Megibow AJ (eds): Imag-
ing of the Pancreas. Cystic and Rare Tumors.

38 Fukushima N, Muki K: Pancreatic neoplasms with abundant mucus production: emphasis
on intraductal papillary-mucinous tumors and

39 Itai Y, Minami I: Mucinous papillary-muci-

nous tumor and mucinous neoplasm: CT and

40 Kimura W, Inoue T, Futakawa N, Shinkai H, Han I, Muto T: Spleen-preserving distal pan-

41 Lukish JR, Rothstein JH, Petruzzelli M, Kite-
ley R, Denobile J, Soballe P: Spleen-preserving

42 Shoup M, Brennan MF, McWhirte K, Leung
DH, Klimstra D, Conlon KC: The value of
splenic preservation with distal pancreacto-

43 Kobayashi G, Fujita N, Noda Y, et al: Histolo-

gical features and prognosis of mucinous cystic
tumors of the pancreas; in Wakui A, Yam-
auchi H, Ouchi K (eds): Carcinoma of the Pancreas and Biliary Tract. Sendai, Tohoku

44 Sagiyma M, Atomi Y: Intraductal papillary
mucinous tumors of the pancreas: an overview

45 Kimura W, Nagai H: Study of surgical ano-

dony for duodenum-preserving resection of the
363.

46 Beger H, Witte C, Krass E, Bittner R: Erfah-

rung mit einer das Duodenum erhaltenden
Pankreasoperationseinteilung bei chronischer Pan-